IL152076D0 - A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines - Google Patents

A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines

Info

Publication number
IL152076D0
IL152076D0 IL15207601A IL15207601A IL152076D0 IL 152076 D0 IL152076 D0 IL 152076D0 IL 15207601 A IL15207601 A IL 15207601A IL 15207601 A IL15207601 A IL 15207601A IL 152076 D0 IL152076 D0 IL 152076D0
Authority
IL
Israel
Prior art keywords
migraines
acute
treatment
pharmaceutical composition
pain
Prior art date
Application number
IL15207601A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US19573800P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to PCT/IB2001/000391 priority patent/WO2001076576A2/en
Publication of IL152076D0 publication Critical patent/IL152076D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
IL15207601A 2000-04-07 2001-03-16 A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines IL152076D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US19573800P true 2000-04-07 2000-04-07
PCT/IB2001/000391 WO2001076576A2 (en) 2000-04-07 2001-03-16 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

Publications (1)

Publication Number Publication Date
IL152076D0 true IL152076D0 (en) 2003-05-29

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15207601A IL152076D0 (en) 2000-04-07 2001-03-16 A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines

Country Status (35)

Country Link
US (2) US20010036943A1 (en)
EP (1) EP1272218B1 (en)
JP (1) JP2003530345A (en)
KR (1) KR20030040201A (en)
CN (1) CN1468111A (en)
AP (1) AP200202642A0 (en)
AR (1) AR027773A1 (en)
AT (1) AT291438T (en)
AU (1) AU3768001A (en)
BG (1) BG107138A (en)
BR (1) BR0109837A (en)
CA (1) CA2405142A1 (en)
CR (1) CR6767A (en)
CZ (1) CZ20023214A3 (en)
DE (1) DE60109589T2 (en)
EA (1) EA004930B1 (en)
EE (1) EE200200579A (en)
ES (1) ES2236185T3 (en)
GT (1) GT200100055A (en)
HU (1) HU0301822A3 (en)
IL (1) IL152076D0 (en)
IS (1) IS6560A (en)
MA (1) MA26889A1 (en)
MX (1) MXPA02009817A (en)
NO (1) NO20024734D0 (en)
OA (1) OA12241A (en)
PA (1) PA8515001A1 (en)
PE (1) PE20011307A1 (en)
PL (1) PL365957A1 (en)
SK (1) SK13952002A3 (en)
SV (1) SV2002000377A (en)
TN (1) TNSN01053A1 (en)
WO (1) WO2001076576A2 (en)
YU (1) YU74602A (en)
ZA (1) ZA200207996B (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
CA2423449A1 (en) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
KR100551183B1 (en) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. Process for the Preparation of 1,3-Substituted Indenes and Aryl-Fused Azapolycyclic Compounds
CA2449987C (en) * 2001-06-07 2015-11-03 Christine N. Sang Treatment of central neuropathic pain
AR036040A1 (en) 2001-06-12 2004-08-04 Upjohn Co Multicyclic compounds substituted heteroaryl quinuclidines and pharmaceutical compositions containing them
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab A device for administering a substance to the front of a subject's oral cavity
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
OA12708A (en) 2001-10-02 2006-06-26 Upjohn Co Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2466344A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
AU2002366588A1 (en) * 2001-12-13 2003-06-23 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
EP1481673A4 (en) 2002-02-05 2008-09-24 Ajinomoto Kk Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2003070728A2 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
US6894042B2 (en) 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04011529A (en) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevention and treatment of functional somatic disorders, including stress-related disorders.
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
WO2003097038A1 (en) * 2002-05-14 2003-11-27 Ralph Ryback Method for treating dermatoses and tissue damage
JP2006504634A (en) * 2002-05-15 2006-02-09 アボット・ラボラトリーズAbbott Laboratories Treatment of neuropathic pain
BR0310057A (en) 2002-05-17 2007-04-10 Othera Pharmaceuticals Inc improvement of cataract development and other ophthalmic diseases
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
AU2003280393A1 (en) * 2002-10-17 2004-05-04 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
SI1572725T1 (en) 2002-12-02 2012-08-31 Xenome Ltd Chi-conotoxin peptides having a n-terminal pyroglutamic acid
AU2003302610B2 (en) 2002-12-02 2008-03-20 Xenome Ltd Novel chi-conotoxin peptides (-II)
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PT1578422E (en) 2002-12-20 2007-06-14 Niconovum Ab A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
WO2004078201A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004230915B2 (en) * 2003-04-08 2008-08-07 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2930900C (en) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinations of ziconotide and opioids for reducing pain
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
AU2004291082A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (en) * 2003-12-19 2016-04-28 Pal Kocsis Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
BRPI0516912A2 (en) * 2004-11-24 2009-06-23 Algorx Pharmaceuticals Inc capsaicinoid gel formulation and uses
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
AR058389A1 (en) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocyclic derivatives of sulfa drug to treat obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
JP2007308403A (en) * 2006-05-17 2007-11-29 Kenji Yoshida Skin care preparation
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
CN101074935B (en) * 2006-05-19 2011-03-23 清华大学 Detector array and its apparatus
FR2902341B1 (en) 2006-06-16 2011-02-25 Scras Therapeutic use simultaneous, separate or spread in the time of at least one botulinum neurotoxin, and at least one opiaceous derivative
JP5192485B2 (en) * 2006-07-17 2013-05-08 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドRamot At Tel Aviv University Ltd. Conjugates comprising psychotropic drugs or GABA agonists and organic acids and their use to treat pain and other CNS disorders
WO2008020651A1 (en) * 2006-08-17 2008-02-21 Kyushu University, National University Corporation P2x4 receptor antagonist
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
JP2010504359A (en) * 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Method for delivering volatile anesthetics for local anesthesia and / or pain relief
WO2008073381A2 (en) * 2006-12-11 2008-06-19 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras Use of at least one botulinum neurotoxin for treating pain induced by therapeutic treatments of aids virus.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20100312073A1 (en) * 2008-01-31 2010-12-09 David Yarnitsky Method of predicting pain medication efficacy
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Therapeutic use of at least one botulinum neurotoxin for the treatment of pain in the case of diabetic neuropathy
AU2009241847B2 (en) 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
RS56344B1 (en) 2010-12-22 2017-12-29 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
CN107412173A (en) 2010-12-23 2017-12-01 普渡制药公司 Anti-distort solid oral dosage form
CA2827715A1 (en) * 2011-02-18 2012-08-23 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
ES2387973B1 (en) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Topical compositions containing diaminooxidase for the treatment or prevention of diseases associated with a level of elevated histamine that perform a pain increase.
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
US9434693B2 (en) * 2012-08-16 2016-09-06 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN104758933A (en) * 2014-10-29 2015-07-08 吴鑫欣 Drug and drug delivery system for treating
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
US10463638B2 (en) * 2017-04-12 2019-11-05 Synergistic Therapeutics, Llc Therapeutic neuropathic pain lotion
KR101944113B1 (en) 2017-09-28 2019-01-30 동의대학교 산학협력단 Composition for relieving and improving acute facial pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621707B2 (en) * 1996-10-30 2005-02-16 ファイザー・インク Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction treatment
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
SK15952000A3 (en) * 1998-04-29 2002-06-04 Pfizer Products Inc. Aryl fused azapolycyclic compound, the use thereof and pharmaceutical compositions based thereon
IL137937D0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
HU0301822A3 (en) 2005-06-28
IS6560A (en) 2002-09-20
EE200200579A (en) 2004-06-15
EA004930B1 (en) 2004-10-28
EA200200910A1 (en) 2003-02-27
KR20030040201A (en) 2003-05-22
US20030133951A1 (en) 2003-07-17
ES2236185T3 (en) 2005-07-16
AP200202642A0 (en) 2002-12-31
AT291438T (en) 2005-04-15
PL365957A1 (en) 2005-01-24
EP1272218A2 (en) 2003-01-08
CA2405142A1 (en) 2001-10-18
MA26889A1 (en) 2004-12-20
SK13952002A3 (en) 2003-12-02
EP1272218B1 (en) 2005-03-23
HU0301822A2 (en) 2003-11-28
SV2002000377A (en) 2002-07-03
BG107138A (en) 2003-05-30
CZ20023214A3 (en) 2003-11-12
TNSN01053A1 (en) 2005-11-10
MXPA02009817A (en) 2003-03-27
WO2001076576A3 (en) 2002-06-20
PA8515001A1 (en) 2002-02-21
CR6767A (en) 2004-06-09
DE60109589D1 (en) 2005-04-28
BR0109837A (en) 2003-01-21
US20010036943A1 (en) 2001-11-01
DE60109589T2 (en) 2005-09-01
ZA200207996B (en) 2003-10-20
CN1468111A (en) 2004-01-14
AR027773A1 (en) 2003-04-09
YU74602A (en) 2006-05-25
NO20024734D0 (en) 2002-10-02
OA12241A (en) 2004-01-27
WO2001076576A2 (en) 2001-10-18
GT200100055A (en) 2001-12-31
PE20011307A1 (en) 2001-12-28
JP2003530345A (en) 2003-10-14
AU3768001A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
DK2236133T3 (en) Pharmaceutical composition comprising fentanyl for the treatment of acute or breakthrough pain by sublingual administration
DE60133029D1 (en) Means for the prevention or treatment of psoriasi
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MXPA03001001A (en) Anticonvulsant derivatives useful for the treatment of depression.
AP200202553A0 (en) Hydrogel-driven drug dosage form
PT1282365E (en) Preparation for the prevention and/or treatment of vascular disorders
DE60126829D1 (en) Combination of three substances for the prevention and treatment of arthritis
AU9486901A (en) Coated medical devices
AU1129902A (en) Coated medical devices
IL154699D0 (en) 1alpha-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU2001288707A1 (en) Materials and methods for the treatment or prevention of obesity
ZA200302283B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same.
AU7284901A (en) Composition for the treatment of osteoarthritis
HK1046240A1 (en) Pharmaceutical compositions for the treatment of insulin resistance
HU0201409A3 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
GB0018030D0 (en) Inhalers
IL152179A (en) Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
GB0009591D0 (en) Medical combinations
PL355994A1 (en) Devices for the delivery of drugs having antiprogestinic properties
AU5618401A (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
HK1075881A1 (en) Fluid treatment system
MX217361B (en) Coating and excipient agent for oral or dermal dosage forms.
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
IL155585A (en) Use of the compound (r) - 2 - acetamido - n - benzyl - 3 - methoxypropionamide for the preparation of a pharmaceutical composition for treating allodynia as a major and unique pain symptom independent of the nature of the underlying disease or chronic or phantom pain
ZA200208835B (en) Compounds and methods for the treatment and prevention of bacterial infection.